Daniel P. Fitzgerald

Dr. Daniel P. Fitzgerald is a biomedical scientist with over 30 years of experience in academic research and translational drug development. He earned his Ph.D. from the Biological and Biomedical Sciences Program at Harvard Medical School in 2001, where he studied chromatin remodeling and gene regulation. He completed postdoctoral training at the Queensland Brain Institute, where he investigated neural development and brain stem cells. He then pursued a second fellowship in the Laboratory of Molecular Pharmacology at the National Cancer Institute, focusing on mechanisms of breast cancer brain metastasis.

Dr. Fitzgerald has more than 14 years of experience in the pharmaceutical and biotechnology sectors, leading preclinical and translational research programs in oncology across small-molecule and biologic platforms. His early industry experience involved hands-on work in target discovery, high-throughput screening, pharmacokinetics, and in vivo efficacy modeling. As a research leader in industry, he directed teams advancing therapeutic programs from preclinical development and IND-enabling studies to scientific support of early clinical-stage assets. He has also contributed to preclinical research strategies in solid organ transplantation and immune tolerance.